News Medical4h
Researchers develop T cell growth method that enhances cancer-fighting ability in melanoma model
Findings indicate that altering glucose metabolism in T cells boosts their therapeutic potential against melanoma, paving the ...
Targeted Oncology2d
Response Time and BRAF Status Factor Into IO Selection for Melanoma
During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed how data from the CheckMate-067 and RELATIVITY-047 ...
BRAF Inhibitors Market to Register Incremental Growth During the Study Period (2020–2034) | DelveInsight
The BRAF Inhibitors market is expected to grow significantly in the coming years. This is due to the increasing number of patients being diagnosed with cancer, rise in biomarker testing rates, the ...
PharmiWeb4d
Pfizer’s BRAFTOVI® Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX® ) and mFOLFOX6 ...
Science Daily6d
Combination of dual-targeted therapies and chemotherapy shows high response rates in BRAF-mutated metastatic colorectal cancer
Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...